Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CD58 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CD58 ECD-Fc Fusion Protein High purity (>95%), Endotoxin Controlled (<1 EU/μg). Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View CD58 Products |
| Gene Delivery | CD58 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cell-based adhesion assays. |
View CD58 Products |
| Benchmark Ab | Anti-CD58 Recombinant Antibody Recombinant positive control derived from clinical-grade benchmark sequences. |
View CD58 Products |
| Validator | CD58 siRNA Set For target knockdown verification and specificity controls in functional assays. |
View CD58 Products |
| Related Target A | CD2 The primary physiological counter-receptor for CD58, essential for validating CD58-mediated T-cell/NK-cell co-stimulation. |
View CD2 Products |
| Related Target B | CD47 Complementary immune checkpoint; dual targeting of CD58 and CD47 is emerging as a synergistic strategy in hematological malignancies. |
View CD47 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Epitope masking by complex glycosylation | HEK293 mammalian expression host ensures native post-translational glycosylation patterns. |
| Low-affinity binding kinetics validation | High-purity monomers and Fc-mer fusions calibrated for precise SPR (Surface Plasmon Resonance) and BLI analysis. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay standardization. |
| False Positives | Validated siRNA included for target-specific knockdown verification. |
Live CD58 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The CD58 (LFA-3) to CD2 axis represents a critical costimulatory pathway in human T cells and NK cells. The race for CD58 therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to bispecific engagers and combination therapies aimed at overcoming tumor immune escape. As first-generation therapies reach the clinic, the next wave of R&D is targeting the restoration of CD58 expression in antigen-escaped tumors (such as CAR-T resistant B-cell lymphomas) and developing bispecific modalities that bridge CD58/CD2 signaling to enhance effector cell infiltration.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies / Agonists | Biotech Pioneers, Academic Consortia | T-cell Lymphoma, Autoimmune Diseases | Affinity & Epitope Mapping (Requires Sequence-Verified ECD-Fc) |
| Bispecific / Multispecific Engagers | Global Biopharma, Oncology Innovators | Solid Tumors, Refractory DLBCL | Heterodimer Validation & Adhesion Assays (Requires Lentivirus for Stable Cell Lines) |
| Combination Therapies (with CAR-T) | Cell Therapy Developers | B-cell Malignancies (CAR-T resistance) | Target Knockdown & Rescue Assays (Requires Validated CD58 siRNA & ORF Vectors) |